Enterprise Therapeutics appoints Dr Renu Gupta as CMO
UK-based respiratory drug developer Enterprise Therapeutics has appointed Dr Renu Gupta as chief medical officer (CMO).
Dr Gupta is a physician-scientist and industry leader, with more than 20 years of experience as a CMO, most recently at Promedior, a member of the Swiss Roche (ROG: SIX) group. During a career spanning over 30 years in the biopharmaceutical industry, she has held various roles within research and development, executive management, and as a board member, including at Global Bio-Pharma, Corbus Pharmaceuticals, Breath Therapeutics, Insmed (Nasdaq: INSM), Novartis (NOVN: VX) and Bristol-Myers Squibb (NYSE: BMY).
Dr Gupta has been instrumental in implementing innovative clinical and regulatory strategies and development pathways to advance targets, including for rare disease indications, forming productive private-public sector partnerships, raising capital, and ultimately advancing molecules from drug discovery through approvals in the major global markets, noted Enterprise chief executive John Ford.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze